Sildenafil (Erectile Dysfunction) - Erectile dysfunction combination therapy

You are here : Home > Formulary Search > Sildenafil (Erectile Dysfunction) - Erectile dysfunction combination therapy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NFD1

Restrictions / Comments :

Documentation

Policy Statement

Erectile dysfunction oral and non oral combination treatments - Policy statement PCN 24-2012 - Jun 2

Evidence Review

Erectile dysfunction combination treatments evidence review June 2012

PAD Profile

ChemicalSubstance :

Sildenafil (Erectile Dysfunction)

Indication :

Erectile dysfunction combination therapy

Group Name :

Keywords :

Phosphodiesterase type 5 inhibitors, ED, Impotence, PDE5, PDE-5

Brand Names Include :

Viagra, Nipatra

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Sildenafil (Erectile Dysfunction) is used to treat.

Erectile dysfunction

Other Drugs

Below are listed other drugs that are used to treat Erectile dysfunction combination therapy.

Committee Recommendations (1)

27 Jun 12 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Use of both oral and non-oral combination treatments for erectile dysfunction in patients who had not responded or had a sub-optimal response to monotherapy was considered.The network members concurred that based on the limited available evidence, noting the feedback from clinicians, that combination treatments should not be supported and a BLACK status should be given on the PAD.Please see policy statement from June 2012